Author

I. R. Correa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 4 Biochemistry· 3 Biophysics· 1 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Assay:proteomics· 4 Research Focus:cell signaling & trafficking· 3 Research Focus:chromatin & epigenetic regulation· 3 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Assay:DNA methylation· 2

Frequent Co-Authors

A. Tomas· 5 shared B. Jones· 5 shared S. R. Bloom· 5 shared G. A. Rutter· 4 shared N. Dai· 4 shared P. Pickford· 4 shared D. Hodson· 3 shared E. R. McGlone· 3 shared

Activity by Year

2018-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersPharmacology & Toxicology

A. Tomas

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

GSK-3484862 targets DNMT1 for degradation in cells

Q. Chen, Y. Zeng, J. W. Hwang, B. Liu, N. Dai, I. R. Correa, M. R. Estecio, X. Zhang, M. A. Santos, T. Chen, X. Cheng

This paper shows that GSK-3484862 targets DNMT1 for degradation in cancer cells and mouse embryonic stem cells, leading to DNA hypomethylation without reducing DNMT1 mRNA levels.

NAR Cancer · May 17, 2023Peer-reviewedCancer Biology

RNase H-based analysis of synthetic mRNA 5-prime cap incorporation

S.-H. Chan, J. M. Whipple, N. Dai, T. M. Kelley, K. Withers, G. Tzertzinis, I. R. Correa, G. B. Robb

The paper describes methods to analyze synthetic mRNA 5' cap incorporation using RNase H-based cleavage and simplified purification techniques.

bioRxiv · Feb 2, 2022Biochemistry

RNA binding to human METTL3-METTL14 restricts N6-deoxyadenosine methylation of DNA in vitro

S. Qi, J. Mota, S.-H. Chan, J. Villarreal, N. Dai, S. Arya, R. A. Hromas, M. K. Rao, I. R. Correa, Y. K. Gupta

This study investigates how the METTL3-METTL14 complex binds and methylates DNA and RNA, revealing distinct preferences for single-stranded DNA and structured RNA.

bioRxiv · Jan 8, 2022Biochemistry

The structural basis of mRNA recognition and binding by eukaryotic pseudouridine synthase PUS1

S. Gruenberg, L. A. Doyle, E. J. Wolf, N. Dai, I. R. Correa, E. Yigit, B. L. Stoddard

This study determines the crystal structure of yeast PUS1 bound to an RNA target, revealing how it recognizes and modifies mRNA and tRNA substrates.

bioRxiv · Dec 8, 2021 · PreprintBiophysics

Multi-Factor Authentication of Potential 5' Splice Sites by the Saccharomyces cerevisiae U1 snRNP

S. R. Hansen, I. R. Correa, M. Scalf, L. M. Smith, A. A. Hoskins

This study uses CoSMoS to show that yeast U1 snRNP reversibly selects 5' splice sites through a sequence-dependent, two-step mechanism involving kinetic selection.

bioRxiv · May 18, 2021 · PreprintBiochemistry

Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1

A. Marzook, S. Chen, P. Pickford, M. Lucey, Y. Wang, I. R. Correa, J. Broichhagen, D. Hodson, V. Salem, G. A. Rutter, T. M. Tan, S. R. Bloom, A. Tomas, B. Jones

This study compares the efficacy and affinity of two GLP-1R agonists, P5 and exendin-F1, showing that exendin-F1's lower acute efficacy correlates with sustained insulin secretion and anti-hyperglycaemic effects.

bioRxiv · Apr 1, 2021Pharmacology & Toxicology

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist

P. Pickford, M. Lucey, R.-M. Rujan, E. R. McGlone, S. Bitsi, F. Ashford, I. R. Correa, D. Hodson, A. Tomas, G. Deganutti, C. A. Reynolds, B. M. Owen, T. M. Tan, J. Minnion, S. R. Bloom, B. Jones

This study shows that partial agonism of GLP-1R/GCGR co-agonists improves anti-hyperglycaemic efficacy by reducing β-arrestin-2 recruitment, leading to prolonged glucose-lowering effects and comparable weight loss to liraglutide.

bioRxiv · Mar 2, 2021Pharmacology & Toxicology

Signal bias at glucagon family receptors: rationale and downstream impacts

B. Jones, E. R. McGlone, Z. Fang, P. Pickford, I. R. Correa, A. Oishi, R. Jockers, A. Inoue, S. Kumar, F. Görlitz, C. Dunsby, P. M. French, G. A. Rutter, T. M. Tan, A. Tomas, S. R. Bloom

The paper investigates signal bias at glucagon family receptors, showing biased agonists affect intracellular signaling and insulin secretion differently.

bioRxiv · Apr 26, 2020Pharmacology & Toxicology

The influence of peptide context on signalling and trafficking of glucagon-like peptide-1 receptor biased agonists

Z. Fang, S. Chen, P. Pickford, J. Broichhagen, D. Hodson, I. R. Correa, S. Kumar, F. Gorlitz, C. Dunsby, P. French, G. A. Rutter, T. Tan, S. R. Bloom, A. Tomas, B. Jones

The paper evaluates how peptide context affects GLP-1R signaling and trafficking, showing differences in agonist-mediated responses based on sequence homology and structural features.

bioRxiv · Feb 24, 2020Pharmacology & Toxicology

Agonist binding affinity determines palmitoylation of the glucagon-like peptide-1 receptor and its functional interaction with plasma membrane nanodomains in pancreatic beta cells

T. Buenaventura, W. E. Laughlin, S. Bitsi, T. Burgoyne, Z. Lyu, A. I. Oqua, H. Norman, E. R. McGlone, A. S. Klymchenko, I. R. Correa, A. Walker, A. Inoue, A. Hanyaloglou, G. A. Rutter, S. R. Bloom, , A. Tomas

This study shows that agonist binding affinity affects GLP-1R palmitoylation, nanodomain clustering, and signaling in pancreatic beta cells, influencing insulin secretion.

bioRxiv · Dec 10, 2018Cell Biology